Pomegranate juice intake attenuates the increase in oxidative stress induced by intravenous iron during hemodialysis

Nutrition Research

Volumn 33, Issue 6, 2013, Pages 442-446

  Shema Didi, Lilach ^a   Kristal, Batya ^a,b   Ore, Liora ^c   Shapiro, Galina ^a   Geron, Ronit ^a   Sela, Shifra ^a,b  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

Author keywords

Hemodialysis; Iron; Oxidative stress; Pomegranate juice

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; FERRIC GLUCONATE; INTERLEUKIN 6; MYELOPEROXIDASE; POLYPHENOL; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; INFLAMMATION; MALE; NEUTROPHIL COUNT; OXIDATIVE STRESS; POMEGRANATE JUICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, INTRAVENOUS; AGED; ANEMIA; BEVERAGES; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRUIT; HUMANS; INFLAMMATION; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEUTROPHILS; OXIDATIVE STRESS; PEROXIDASE; PUNICACEAE; RENAL DIALYSIS;

EQUUS ASINUS; LYTHRACEAE;

EID: 84878897432     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2013.04.004     Document Type: Article

References (28)

1. Lim P.S., Wei Y.H., Yu Y.L., Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999, 14(11):2680-2687.
2. Michelis R., Gery R., Sela S., Shurtz-Swirski R., Grinberg N., Snitkovski T., et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003, 18:924-930.
3. Michelis R., Sela S., Kristal B. Intravenous iron-gluconate during haemodialysis modifies plasma β2-microglobulin properties and levels. NDT 2005, 20:1963-1969.
4. Rooyakkers T., Stroes E., Kooistra M., et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002, 32:9-16.
5. Salahudeen A., Oliver B., Bower J., Roberts J. Increase in plasma esterified F2 isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001, 60:1525-1531.
6. Herrera J., Nava M., Romero F., Rodriguezpiturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001, 37:750-757.
7. Schwedler S., Schinzel R., Vaith P., Wanner C. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship?. Kidney Int Suppl 2001, 78:S32-S36.
8. Sela S., Shurtz-Swirski R., Shapiro G., Nasser L., Hamzi M., Shasha S.M., et al. Oxidative stress during hemodialysis: effect of heparin. Kidney Int Suppl 2001, 78:S159-S163.
9. Espósito B.P., Breuer W., Slotki I., Cabantchik Z.I. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002, 32:42-49.
10. Parkkinen J., von Bonsdorff L., Peltonen S., Grönhagen-Riska C., Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000, 15(11):1827-1834.
11. Sela S., Shurtz-Swirski R., Cohen-Mazor M., Mazor R., Chezar J., Shapiro G., et al. Primed peripheral polymorphnuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 2005, 16:2431-2438.
12. Ono K., Ueki K., Inose K., Tsuchida A., Yano S., Nojima Y. Plasma levels of myeloperoxidase and elastase are differentially regulated by hemodialysis membranes and anticoagulants. Res Commun Mol Pathol Pharmacol 2000, 108(5-6):341-349.
13. Spormann T., Albert F., Rath T., Dietrich H., Will F., Stockis J.P., et al. Anthocyanin/Polyphenolic-rich fruit juice reduces oxidative cell damage in an intervention study with patients on hemodialysis. Cancer Epidemiol Biomarkers Prev 2008, 17:3372-3380.
14. Gil M.I., Tomás-Barberán F.A., Hess-Pierce B., Holcroft D.M., Kader A.A. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000, 48:4581-4589.
15. Seeram N.P., Aviram M., Zhang Y., Henning S.M., Feng L., Dreher M., et al. Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States. J Agric Food Chem 2008, 56(4):1415-1422.
16. Pantuck A.J., Leppert J.T., Zomorodian N., Aronson W., Hong J., Barnard R.J., et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006, 12(13):4018-4026.
17. Basu A., Penugonda K. Pomegranate juice: a heart-healthy fruit juice. Nutr Rev 2009 Jan, 67(1):49-56. 10.1111/j.1753-4887.2008.00133.x.
18. Shema-Didi L., Sela S., Ore L., Shapiro G., Geron R., Moshe G., et al. One year of pomegranate juice intake decreases oxidative stress, inflammation and incidence of infections in hemodialysis patients: a randomized placebo-controlled trial. Free Radic Biol Med 2012, 53:297-304.
19. Ben Nasr C., Ayed N., Metche M. Quantitative determination of the polyphenolic content of pomegranate peel. Z Lebensm Unters Forsch 1996, 203:374-378.
20. Dumville J.C., Hahn S., Miles J.N., Torgerson D.J. The use of unequal randomisation ratios in clinical trials: a review. Contemp Clin Trials 2006, 27(1):1-12.
21. Wu C.C., Chen J.S., Wu W.M., Liao T.N., Chu P., Lin S.H., et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant 2005, 20(6):1134-1139.
22. Witko-Sarsat V., Freidlander M., Capeillere-Blandin C., Nguyen-Khoa T., Nguyen A., Zingraff J., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996, 49:1304-1313.
23. Albaramki J., Hodson E.M., Craig J.C., Webster A.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012, 18:1. CD007857.
24. Borawski J. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. Am J Kidney Dis 2006, 47(1):37-41.
25. Roob J., Khoschsorur G., Tiran A., Horina J., Holzer H., Winklhofer-Roob B. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000, 11:539-549.
26. Jacobi J., Sela S., Cohen H., Chezar J., Kristal B. Priming of polymorphonuclear leukocytes: a culprit in the initiation of endothelial cell injury. Am J Physiol Heart Circ Physiol 2005, 290:H2051-H2058.
27. Descamps-Latscha B., Jungers P., Witko-Sarsat V. Immune system dysregulation in uremia: role of oxidative stress. Blood Purif 2002, 20:481-484.
28. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin A, Marchais S, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002;106:2212-7.